International Journal of Current Research in Physiology and Pharmacology
Volume 7, Supplement 2; 2023
eISSN: 2523-6709 pISSN: 2523-6695 *Review Article*

Aspirin Unveiled: Shielding Hearts from Coronary Artery Disease

Abrar Bashir Malik Department of Pharmacology, CT Institute of Pharmaceutical Sciences, PTU, Jalandhar, Punjab, India.
Mashooq Ahmad Mir Department of Pharmacology, CT Institute of Pharmaceutical Sciences, PTU, Jalandhar, Punjab, India.
Zulfkar Qadrie Department of Pharmacology, Government Medical College Baramulla, India.
*Mohd Altaf Dar** Department of Pharmacology, CT Institute of Pharmaceutical Sciences, PTU, Jalandhar Punjab, India.

**Corresponding Author*

ABSTRACT

In the realm of cardiovascular protection, aspirin emerges as a potent sentinel against Coronary Artery Disease (CAD). Beyond its well-known pain-relief properties, aspirin's remarkable antiplatelet action takes center stage. By inhibiting platelet aggregation through COX-1 enzyme suppression, aspirin mitigates the formation of arterial thrombi, crucial in averting heart attacks and strokes. Aspirin's role spans both secondary and selective primary prevention. In secondary prevention, it stands as a stalwart defense, substantially lowering the risk of recurrent cardiovascular events. In primary prevention, its application is tailored to high-risk individuals, although careful consideration of bleeding risks is paramount. Yet, aspirin is not immune to scrutiny. Concerns include potential bleeding complications, gastric irritation, and drug interactions. In this evolving landscape, its application aligns with emerging guidelines, fine-tuning its role in CAD management. "Aspirin Unveiled: Shielding Hearts from Coronary Artery Disease" encapsulates aspirin's pivotal stance in cardiovascular protection. As a guardian of platelet activity, it plays a crucial role in curbing CAD's impact, symbolizing hope in the battle for heart health.

Keywords: Coronary artery disease, Heart, Management.

Introduction

Coronary artery disease (CAD) remains a leading cause of morbidity and mortality worldwide, posing a significant public health challenge. Various interventions have been developed to manage CAD, and among them, aspirin has emerged as a cornerstone therapy. Aspirin, also known as acetylsalicylic acid, exerts its primary pharmacological effect through irreversible inhibition of cyclooxygenase (COX) enzymes, particularly COX-1 [1-5]. This inhibition leads to decreased production of thromboxane A2, a potent platelet aggregator and vasoconstrictor. By inhibiting thromboxane synthesis, aspirin reduces platelet activation and aggregation, which are central to the formation of arterial thrombi. The antiplatelet effect of aspirin contributes to the prevention of acute thrombotic events in CAD. Aspirin, or acetylsalicylic acid, is renowned for its analgesic and anti-inflammatory properties [5-10]. However, its profound impact on CAD stems from its antiplatelet effects. Aspirin’s mechanism of action centers on the inhibition of cyclooxygenase (COX) enzymes, particularly COX-1, which leads to a reduction in thromboxane A2 production—a potent platelet aggregator and vasoconstrictor. By diminishing thromboxane synthesis, aspirin curtails platelet activation and aggregation, thwarting the formation of arterial thrombi, the primary culprits behind myocardial infarctions and ischemic strokes. The benefits of aspirin in CAD

are multifaceted and well-documented. In secondary prevention, aspirin plays a crucial role in patients with established CAD, significantly reducing the risk of recurrent cardiovascular events [10-15]. Numerous trials and meta-analyses, including the landmark Antiplatelet Trialists' Collaboration, have underscored aspirin's effectiveness in decreasing major vascular events and mortality rates in this context. As a pivotal component of post-acute coronary syndrome (ACS) management, aspirin's antiplatelet action collaborates with other agents like P2Y12 inhibitors to mitigate further thrombus formation, thereby preventing catastrophic outcomes. In primary prevention, aspirin's role is nuanced and depends on the patient's risk profile. High-risk individuals, such as those with multiple risk factors, may benefit from aspirin therapy to reduce the likelihood of their first cardiovascular event. However, the decision to initiate aspirin hinges on a careful assessment of the patient's overall risk, considering factors such as age, gender, and bleeding susceptibility. Balancing potential cardiovascular benefits with bleeding risks is essential in making informed clinical decisions [15-20].

Mechanism of Action of Aspirin in coronary artery disease

The mechanism of action of aspirin in coronary artery disease (CAD) revolves around its antiplatelet properties. Aspirin, also known as acetylsalicylic acid, functions by irreversibly inhibiting the enzyme cyclooxygenase (COX), particularly COX-1 [20-25]. This inhibition leads to a cascade of biochemical events that play a critical role in preventing thrombotic events associated with CAD. COX enzymes are responsible for converting arachidonic acid into prostaglandins, which have various physiological functions, including platelet aggregation and vasoconstriction. COX-1, specifically found in platelets, plays a key role in generating thromboxane A2, a potent mediator of platelet aggregation and vasoconstriction [25-30]. Thromboxane A2 promotes the clumping of platelets together, leading to the formation of blood clots that can block coronary arteries, resulting in heart attacks or other ischemic events [30-35].

Aspirin's intervention in this process is twofold

1. COX Inhibition: Aspirin covalently acetylates a specific serine residue within the active site of COX-1. This acetylation irreversibly inactivates the enzyme, thereby preventing the production of thromboxane A2. With reduced thromboxane A2 synthesis, platelet activation is curtailed, leading to decreased platelet aggregation [35-40].

2. Antiplatelet Effect: By inhibiting thromboxane A2 production, aspirin effectively dampens the signaling pathway that triggers platelet activation and aggregation. As a result, the risk of platelet-rich clots forming in coronary arteries is diminished, reducing the likelihood of acute coronary events [40-45].

This antiplatelet action is pivotal in CAD management, particularly in preventing acute events such as myocardial infarctions and ischemic strokes. Aspirin's impact extends beyond the coronary arteries, as it has similar effects on other blood vessels throughout the body, contributing to its broader role in preventing vascular events [45-50]. While aspirin's antiplatelet mechanism is well-established, it's important to note that its usage must be carefully considered based on individual patient characteristics and risk factors. The potential for bleeding complications, particularly in certain populations, necessitates a balanced assessment of benefits versus risks when prescribing aspirin for CAD prevention or management [50-55].

Benefits of aspirin in coronary artery disease

The benefits of aspirin in coronary artery disease (CAD) are rooted in its remarkable ability to modulate platelet activity and reduce the risk of thrombotic events. CAD is characterized by the gradual buildup of atherosclerotic plaque within coronary arteries, leading to narrowed and compromised blood flow. Aspirin's role in CAD management revolves around its antiplatelet properties, which play a pivotal role in preventing acute cardiovascular events [55-60].

1. Antiplatelet Effect: Aspirin's mechanism of action hinges on its inhibition of cyclooxygenase (COX) enzymes, with COX-1 being the primary target. COX enzymes are responsible for the conversion of arachidonic acid into thromboxane A2, a potent mediator of platelet aggregation and vasoconstriction. By acetylating COX-1 irreversibly, aspirin effectively curtails the production of thromboxane A2. This disruption in platelet activation and aggregation cascade leads to a reduction in the formation of blood clots, the critical culprits underlying myocardial infarctions and ischemic strokes [60-65].

2. Secondary Prevention: Aspirin's effectiveness in secondary prevention is well-established. For individuals who have already experienced a heart attack, unstable angina, or other CAD-related events, aspirin therapy significantly lowers the risk of recurrent cardiovascular events. Numerous clinical trials and meta-analyses, such as the Antiplatelet Trialists' Collaboration, have demonstrated aspirin's ability to reduce the incidence of major vascular events and mortality rates in this population [65-70].

3. Acute Coronary Syndrome (ACS): In the acute phase of CAD, such as during an acute coronary syndrome (ACS) like a heart attack, aspirin's rapid action is crucial. Alongside other antiplatelet agents like P2Y12 inhibitors (e.g., clopidogrel), aspirin is administered to rapidly inhibit platelet activation, thereby preventing the formation of larger and more obstructive clots. This early intervention minimizes the extent of myocardial damage and improves outcomes in ACS patients [70-75].

4. Primary Prevention: Aspirin's role in primary prevention of CAD is subject to careful consideration. In specific high-risk individuals, such as those with multiple risk factors (diabetes, hypertension, hyperlipidemia), aspirin may be considered to mitigate the risk of a first cardiovascular event. However, the decision to initiate aspirin for primary prevention must weigh the potential benefits against the risks of bleeding, particularly in lower-risk populations [75-80].

5. Long-Term Outcomes: The benefits of aspirin extend beyond immediate event prevention. By reducing the occurrence of recurrent cardiovascular events, aspirin contributes to improved long-term outcomes and enhanced quality of life for individuals living with CAD [80-85].

While aspirin offers these compelling benefits, its use is not without considerations. Bleeding risks, particularly gastrointestinal and intracranial bleeding, are notable potential adverse effects. Additionally, aspirin's impact on gastric mucosa can lead to irritation, prompting the use of enteric-coated or buffered formulations to mitigate this risk. Aspirin's role in coronary artery disease is rooted in its ability to counteract platelet activation and aggregation, pivotal processes in the formation of arterial thrombi. Its benefits encompass both secondary and selective primary prevention, as well as its integral role in managing acute coronary syndromes. However, the decision to use aspirin should be based on a comprehensive assessment of individual patient factors and guided by current medical guidelines. Regular communication between patients and healthcare providers is essential to ensure an informed and personalized approach to CAD management with aspirin therapy [86].

Potential risks and considerations

The use of aspirin in coronary artery disease (CAD) offers significant benefits, but it also comes with potential risks and considerations that need to be carefully weighed when making treatment decisions.

1. Bleeding Complications: Aspirin's antiplatelet effect increases the risk of bleeding, which can range from minor bruising to more serious gastrointestinal bleeding or even intracranial hemorrhage. The risk of bleeding is particularly relevant for individuals with a history of bleeding disorders, gastrointestinal ulcers, or other conditions that affect blood clotting [87].

2. Gastrointestinal Irritation: Aspirin can irritate the stomach lining, potentially leading to gastrointestinal discomfort, ulcers, or bleeding. To mitigate this risk, enteric-coated or buffered formulations of aspirin may be used, which are designed to dissolve in the small intestine rather than the stomach [88].

3. Drug Interactions: Aspirin can interact with other medications, potentially affecting their effectiveness or safety. Individuals who are on multiple medications should be closely monitored for potential interactions, and adjustments to dosages or medications may be necessary [89,90].

4. Allergic Reactions: While rare, some individuals may experience allergic reactions to aspirin, which can range from mild skin rashes to more severe respiratory symptoms like asthma exacerbation or anaphylaxis [91].

5. Reye's Syndrome: Aspirin use in children and teenagers with viral infections has been associated with Reye's syndrome, a rare but potentially life-threatening condition that affects the liver and brain. As a result, aspirin is generally avoided in this population [92].

6. Impact on Kidneys: Prolonged use of aspirin may have an impact on kidney function, particularly in individuals with preexisting kidney disease. Close monitoring of kidney function is recommended in such cases [93].

7. Hypersensitivity: Some individuals may develop hypersensitivity or intolerance to aspirin over time, which can manifest as worsening symptoms or adverse reactions [94].

8. Drug Resistance: In some cases, individuals may not respond adequately to aspirin therapy, leading to reduced effectiveness in preventing platelet aggregation and thrombotic events [94-100].

Given these potential risks and considerations, it is essential for healthcare providers to conduct a thorough assessment of each patient's medical history, risk factors, and current medications before prescribing aspirin for CAD prevention or management. The decision to use aspirin should be based on an individualized approach that carefully balances the benefits of its antiplatelet effects with the potential risks of bleeding and other adverse effects. Regular communication and monitoring are critical to ensuring that aspirin therapy remains safe and effective for patients with CAD [95-100].

Current guidelines and recommendations

1. Secondary Prevention: Aspirin is well-established and widely recommended for secondary prevention in patients with established CAD, especially after acute events such as myocardial infarction (heart attack) or following revascularization procedures (angioplasty, stenting, bypass surgery). Most guidelines suggest daily low-dose aspirin (usually 81 mg) for long-term use in these patients [100-103].

2. Primary Prevention: The use of aspirin for primary prevention in individuals without known CAD but at high cardiovascular risk is more nuanced. Current recommendations vary based on different guidelines. Some guidelines suggest considering aspirin in high-risk individuals with multiple risk factors (e.g., diabetes, smoking, hypertension) and a calculated high cardiovascular risk. However, other guidelines are more cautious due to the potential bleeding risk and recommend shared decision-making between the patient and healthcare provider [103-107].

3. Low-Risk Populations: Routine aspirin use for primary prevention in low-risk populations is generally not recommended due to the potential for bleeding complications outweighing the potential benefits [107,108].

4. Patient Assessment: Before initiating aspirin therapy, healthcare providers should assess individual patient characteristics, including age, bleeding risk, history of bleeding disorders, and

concomitant medications [108-111].

5. Antiplatelet Therapy in ACS: Aspirin remains a cornerstone in the management of acute coronary syndrome (ACS), often combined with other antiplatelet agents such as P2Y12 inhibitors (e.g., clopidogrel) and anticoagulants in specific ACS settings [111-115].

6. Personalized Approach: Current guidelines emphasize a personalized approach to aspirin therapy, taking into account both the potential benefits and risks for each patient. This includes assessing individual bleeding risk and considering alternative antiplatelet therapies when appropriate [115-120].

Please note that these are general guidelines, and individual recommendations may vary based on the specific patient's medical history and risk factors. It has crucial to consult with a healthcare professional to determine the most suitable approach to aspirin therapy in the context of coronary artery disease. Additionally, since medical guidelines can change over time, it is important to stay updated with the latest recommendations from reputable medical organizations [121].

Conclusion

Aspirin, due to its antiplatelet effects, plays an important role in the treatment of coronary artery disease by reducing the risk of recurrent thrombotic events and improving patient outcomes. However, use should be tailored to the individual characteristics of the patient, taking into account the balance between cardiovascular benefits and potential risks. As research continues to refine our understanding of the role of aspirins, healthcare providers need to stay abreast of evolving guidelines to ensure optimal care for patients with CAD.

References

1. P.A.J. C.J.o.t.A.S.o.N. McCullough. Coron Artery Dis. 2007;2(3):611-6.
2. Maqbool M, Bekele F, Fekadu GJBCT. Therapy, Treatment strategies against triple-
3. negative breast cancer: an updated review; 2022. p. 15-24.
4. Libby P, Theroux PJC. Pathophysiology of coronary artery disease. Circulation. 2005;111(25):3481-8. doi: 10.1161/CIRCULATIONAHA.105.537878, PMID 15983262.
5. Zehravi M, Maqbool M, Ara IJIjoam. Polycystic ovary syndrome and infertility: an update. Int J Adolesc Med Health. 2021;34(2):1-9. doi: 10.1515/ijamh-2021-0073, PMID 34293835.
6. Fuster V, Badimon L, Badimon JJ. Chesebro, The pathogenesis of coronary artery disease and the acute coronary syndromes, J.H.J.N.E.j.o.m. 1992;326(4):242-50.
7. Maqbool R, Maqbool M, Zehravi M, Ara IJIjoam. Menstrual distress in females of reproductive age: a literature review. Int J Adolesc Med Health. 2021;34(2):11-7. doi: 10.1515/ijamh-2021-0081, PMID 34293834.
8. Hertzer NR, Beven EG, Young JR, O'Hara PJ, Ruschhaupt W.F. 3rd, Graor RA et al. Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. Ann Surg. 1984;199(2):223-33. doi: 10.1097/00000658-198402000-00016, PMID 6696538.
9. Zehravi M, Maqbool M, Ara I. Correlation between obesity, gestational diabetes mellitus, and pregnancy outcomes: an overview. Int J Adolesc Med Health. 2021;33(6):339-45. doi: 10.1515/ijamh-2021-0058, PMID 34142511.
10. Shao C, Wang J, Tian J, Tang Y-dJCADT, D. Discovery, coronary artery disease: from mechanism to clinical practice; 2020. p. 1-36.
11. Ralapanawa U, Sivakanesan RJJoe. Epidemiology and the magnitude of coronary artery disease and acute coronary syndrome: a narrative review. J Epidemiol Glob Health. 2021;11(2):169-77. doi: 10.2991/jegh.k.201217.001, PMID 33605111.
12. Zehravi M, Maqbool M, Ara I. Depression and anxiety in women with polycystic ovarian syndrome: a literature survey. Int J Adolesc Med Health. 2021;33(6):367-73. doi:

10.1515/ijamh-2021-0092, PMID 34420269.
13. Bauersachs R, Zeymer U, Brière J.B., Marre C, Bowrin K, Huelsebeck MJCt. Burden of coronary artery disease and peripheral artery disease: a literature review. Cardiovasc Ther. 2019;2019:8295054. doi: 10.1155/2019/8295054, PMID 32099582.
14. Abdar M, Książek W, Acharya UR, Tan R-S, Makarenkov V, Pławiak PJCm. biomedicine, A new machine learning technique for an accurate diagnosis of coronary artery disease. 2019;179:104992.
15. Lihite RJ, Lahkar M, Das S, Hazarika D, Kotni M, Maqbool M et al. A study on adverse drug reactions in a tertiary care hospital of Northeast India. Alexandria Journal of Medicine. 2017;53(2):151-6. doi: 10.1016/j.ajme.2016.05.007.
16. Barham A, Ibraheem R, S.e.H.J.B.C.D. Zyoud, Cardiac self-efficacy and quality of life in patients with coronary heart disease: a cross-sectional study from Palestine. 2019;19(1):1-12.
17. Zehravi M, Maqbool M, Ara IJOH. Healthy lifestyle and dietary approaches to treating polycystic ovary syndrome: a review. Open Health. 2022;3(1):60-5. doi: 10.1515/openhe-2022-0008.
18. Zehravi M, Maqbool M, IJIJoAM. Ara, Health, Teenage menstrual dysfunction: an overview. 2022;35(1):15-9.
19. Higashi Y, Gautam S, Delafontaine P, Sukhanov SJGH, I. Research, IGF-1 and cardiovascular disease. 2019;45:6-16.
20. Ornish D, Brown SE, Billings J, Scherwitz L, Armstrong WT, Ports TA et al. Can lifestyle changes reverse coronary heart disease?: the Lifestyle Heart Trial. 1990;336(8708):129-33.
21. Rutledge JC, Hyson DA, Garduno D, Cort DA, Paumer L, CTJJoCR. Kappagoda, Prevention, Lifestyle modification program in management of patients with coronary artery disease: the clinical experience in a tertiary care hospital. 1999;19(4):226-34.
22. Majeed A, Bashir R, Farooq S, Maqbool MJJoDD. Therapeutics, Preparation, characterization and applications of nanoemulsions: an insight. 2019;9(2):520-7.
23. Khan S, Cleanthis M, Smout J, Flather M, Stansby GJEJoV, E. Surgery, Lifestyle modification in peripheral arterial disease. 2005;29(1):2-9.
24. M, Maqbool M, Dar MA, Mushtaq IJJoDD. Mohd. Ther Polycystic Ovary Syndr Mod Epidemic Overview. 2019;9(3):641-4.
25. Winzer EB, Woitek F, A.J.J.o.t.A.H.A. Linke, Physical activity in the prevention and treatment of coronary artery disease. 2018;7(4):e007725.
26. Maqbool M, Gani I, M.A.J.A.J.o.P.R. Dar, Development, Antidiabetic effects of some medicinal plants in experimental animals: a review. 2019;7(1):66-9.
27. Claes J, Buys R, Budts W, Smart N, Cornelissen V.A. Longer-term effects of home-based exercise interventions on exercise capacity and physical activity in coronary artery disease patients: A systematic review and meta-analysis. Eur J Prev Cardiol. 2017;24(3):244-56. doi: 10.1177/2047487316675823, PMID 27798366.
28. Ara I, Maqbool M. Gani, Pharmacology, Reproductive Health of Women: implications and attributes. I.J.I. Jo.C.R.i.P. 2022:8-18.
29. Goldenberg I, Jonas M, Tenenbaum A, Boyko V, Matetzky S, Shotan A et al.G.J.A.o.i. medicine, Current smoking, smoking cessation, and the risk of sudden cardiac death in patients with coronary artery disease. 2003;163(19):2301-5.
30. Bashir R, Maqbool M, Ara I, Zehravi MJC. An in sight into Novel Drug Delivery System: in situ Gels. 2021;11(1):6.1-7.
31. Ludvig J, Miner B, Eisenberg M.J. Smoking cessation in patients with coronary artery disease. Am Heart J. 2005;149(4):565-72. doi: 10.1016/j.ahj.2004.09.040, PMID 15990735.
32. Maqbool M, Fekadu G, Dugassa D, Bekele F, Turi E, Simegnew DJAoN. The pattern of substance abuse in the psychiatry department of a tertiary care of Srinagar hospital, Jammu and Kashmir, India. Arch Neurosci. 2020;7(4). doi: 10.5812/ans.106492.
33. Ades PA, Savage P.D. Potential benefits of weight loss in coronary heart disease. Prog Cardiovasc Dis. 2014;56(4):448-56. doi: 10.1016/j.pcad.2013.09.009, PMID 24438737.
34. Fekadu G, Bekele F, Bekele K, Hanbisa S, Belay G, Maqbool MJCT. Drug use evaluation of beta-blockers in medical wards of Nedjo general hospital, Western Ethiopia. Cardiovasc

Ther. 2020;2020:2509875. doi: 10.1155/2020/2509875, PMID 32565908.
35. Pack QR, Rodriguez-Escudero JP, Thomas RJ, Ades PA, West CP, Somers VK et al. The prognostic importance of weight loss in coronary artery disease: a systematic review and meta-analysis. Mayo Clin Proc. 2014;89(10):1368-77. doi: 10.1016/j.mayocp.2014.04.033, PMID 25199859.
36. Ara I, Zehravi M, Maqbool M, Gani IJJoPR, RSJ-Dd. doi: 10.47363/JPRSR/, A review of recent developments and future challenges in the implementation of universal health coverage policy framework in some countries, 127 2022.
37. Michalsen A, Grossman P, Lehmann N, Knoblauch NT, Paul A, Moebus S et al. psychosomatics, Psychological and quality-of-life outcomes from a comprehensive stress reduction and lifestyle program in patients with coronary artery disease: results of a randomized trial. 2005;74(6):344-52.
38. Maqbool M, Dugassa D, Fekadu GJAoN. Adverse drug reactions of antiepileptic drugs in the neurology department of a tertiary care hospital, Srinagar, Jammu & Kashmir, India. Arch Neurosci. 2021;8(2). doi: 10.5812/ans.112364.
39. Mathews MJ, Liebenberg L, Mathews EHJNj. The mechanism by which moderate alcohol consumption influences coronary heart disease. Nutr J. 2015;14:33. doi: 10.1186/s12937-015-0011-6, PMID 25889723.
40. Maqbool M, Zehravi M, Maqbool R, Ara IJC. An overview about treatment of gestational diabetes mellitus: A short communication. 2021;11(3):12.1-5.
41. Matsumoto C, Miedema MD, Ofman P, Gaziano JM, Sesso H.D. An expanding knowledge of the mechanisms and effects of alcohol consumption on cardiovascular disease. J Cardiopulm Rehabil Prev. 2014;34(3):159-71. doi: 10.1097/HCR.0000000000000042, PMID 24667667.
42. Zehravi M, Maqbool M, IJIJoAM. Ara, Health, Unfolding the mystery of premenstrual syndrome (PMS): an overview. 2022;35(1):9-13.
43. Maddox TM, Ho P.M. Ho. Medication adherence and the patient with coronary artery disease: challenges for the practitioner. Curr Opin Cardiol. 2009;24(5):468-72. doi: 10.1097/HCO.0b013e32832ed62d, PMID 19550308.
44. Ara I, Maqbool M, Bukhari B, Ara N. Hajam, Technology, Present status, standardization and safety issues with herbal drugs. T J;I.J.o.R.i.P.S:1(3) (2020) 95-101.
45. Baroletti S, Dell'Orfano HJC. Medication adherence in cardiovascular disease. Circulation. 2010;121(12):1455-8. doi: 10.1161/CIRCULATIONAHA.109.904003, PMID 20351303.
46. Ara I, Maqbool M. Gani, pharmacology, neuroprotective activity of herbal medicinal products: a review. I.J.I. Jo.C.R.i.P. 2022:1-10.
47. Mendez CB, Salum NC, Junkes C, Amante LN, C.M.L.J.R.l.-a.d.e. Mendez, Mobile educational follow-up application for patients with peripheral arterial disease. Vol. 27; 2019.
48. Maqbool M, Rasool S, Dar MA, Bashir R, Khan MJP. Hepatotoxicity and hepatoprotective agents: A Mini review. 2019;7(9):34-40.
49. Zhou DT, Oektedalen O, Shawarira-Bote S, Stray-Pedersen BJHA-R, Care P. Changes in coronary heart disease risk profiles of HIV patients in Zimbabwe over 9 months: a follow-up study. HIV AIDS (Auckl). 2016;8:165-74. doi: 10.2147/HIV.S113206, PMID 27822124.
50. Maqbool M, Dar AM, Rasool S, MJJoAPS. Khan, Research, Curious case of drug resistant malaria and artemisinine compounds in the modern era; 2019. p. 1-4.
51. Maqbool M, Zehravi MJIPM. Neuromodulation, neuroprotective role of polyphenols in treatment of neurological disorders: a review. Vol. 1(1); 2021.
52. Hankey GJ, Norman PE, Eikelboom JWJJ. Medical treatment of peripheral arterial disease. J.A.M.A. 2006;295(5):547-53. doi: 10.1001/jama.295.5.547, PMID 16449620.
53. Rayan RA, Zafar I, Rajab H, Zubair MAM, Maqbool M, SJMLAfS et al. Processing, impact of IoT in biomedical applications using machine and deep learning; 2022. p. 339-60.
54. Ara I, Maqbool M, Fekadu G, Hajam TA. Dar, Research, Pharmaceutical significance of Nigella sativa L., a wonder herb. M J.J.o.A.P.S. 2020;3(4):04-13.
55. B.D.S.G.J.N.E.J.o. Medicine, A randomized trial of therapies for type 2 diabetes and coronary artery disease. 2009;360(24):2503-15.
56. Maqbool R, Maqbool M, Zehravi M, Ara I. Acute neurological conditions during pregnancy and their management: a review. Int J Adolesc Med Health. 2021;33(6):357-66. doi:

10.1515/ijamh-2021-0084, PMID 34420267.
57. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch J.H..J.T.A.j.o.c. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol. 2001;87(7):819-22. doi: 10.1016/s0002-9149(00)01519-8, PMID 11274933.
58. Maqbool M, Zehravi M, Maqbool R, Ara IJC. Study of adverse drug reactions in pulmonary medicine department of a tertiary care hospital, Srinagar, Jammu and Kashmir, India. 2021;11(2):8.1-5.
59. Tran H, Anand SSJJ. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. J.A.M.A. 2004;292(15):1867-74. doi: 10.1001/jama.292.15.1867, PMID 15494585.
60. Zehravi M, Maqbool R, Maqbool M, IJJoPRI. Ara, to identify patterns of drug usage among patients who seek care in psychiatry outpatient department of a Tertiary Care Hospital in Srinagar, Jammu and Kashmir, India. 2021;33(31A):135-40.
61. Clappers N, Brouwer M.A., Verheugt F.W. Antiplatelet treatment for coronary heart disease. Heart. 2007;93(2):258-65. doi: 10.1136/hrt.2005.071209, PMID 17228079.
62. M.J.J.o.A.P.S. Maqbool, Research, Evaluation of drug utilization pattern in the pediatric department of a Tertiary Care Hospital in Srinagar, Jammu & Kashmir, India, 2019 6-9.
63. Rauch U, Osende J.I., Chesebro J.H., Fuster V, Vorchheimer D.A., Harris K et al. Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins. Atherosclerosis. 2000;153(1):181-9. doi: 10.1016/s0021-9150(00)00397-x, PMID 11058714.
64. Mihos CG, Pineda AM, Santana OJPr. Cardiovascular effects of statins, beyond lipid-lowering properties. Pharmacol Res. 2014;88:12-9. doi: 10.1016/j.phrs.2014.02.009, PMID 24631782.
65. Tousoulis D, Charakida M, Stefanadi E, Siasos G, Latsios G, Stefanadis CJIjoc. Statins in heart failure. Beyond the lipid lowering effect. Int J Cardiol. 2007;115(2):144-50. doi: 10.1016/j.ijcard.2006.03.094, PMID 17175040.
66. Maqbool M, Gani IJJoPP, Medicine C. Utilization of statins in reducing comorbidities of diabetes mellitus: A systematic review. JPPCM. 2018;4(4):193-6. doi: 10.5530/jppcm.2018.4.46.
67. Paravastu S, Mendonca D, Da Silva AJEjov. surgery, beta blockers for peripheral arterial disease. 2009;38(1):66-70.
68. Ara I, Maqbool M. Gani, Pharmacology, Specificity and Personalized medicine: a novel approach to Cancer management. I.J.I. Jo.C.R.i.P. 2022:11-20.
69. Chonchol M, Benderly M, Goldbourt UJNDT. Beta-blockers for coronary heart disease in chronic kidney disease. Nephrol Dial Transplant. 2008;23(7):2274-9. doi: 10.1093/ndt/gfm950, PMID 18187497.
70. Leong DP, McMurray JJ, Joseph PG, S.J.J.o.t.A.C.o.C. Yusuf, From ACE inhibitors/ARBs to ARNIs in coronary artery disease and heart failure. part 2/5, 74(5); 2019. p. 683-98.
71. Gillespie EL, White CM, Kardas M, Lindberg M, Coleman CIJDc. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care. 2005;28(9):2261-6. doi: 10.2337/diacare.28.9.2261, PMID 16123505.
72. Dar MA, Maqbool M, Gani I. Ara, Pharmacology, menstruation hygiene and related issues in adolescent girls: A brief commentary. I.J.I. Jo.C.R.i.P. 2023:1-5.
73. Hoang V, Alam M, Addison D, Macedo F, Virani S, Birnbaum YJCd. Efficacy of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in coronary artery disease without heart failure in the modern statin era: a meta-analysis of randomized-controlled trials. Cardiovasc Drugs Ther. 2016;30(2):189-98. doi: 10.1007/s10557-016-6652-7, PMID 26861251.
74. Maqbool M, Khan MJP. Hypertension and Pregnancy: an important issue. 2019;7(8):71-8.
75. GORLIN R, BRACHFELD N, MACLEOD C, BOPP PJC. Effect of nitroglycerin on the coronary circulation in patients with coronary artery disease or increased left ventricular work. Circulation. 1959;19(5):705-18. doi: 10.1161/01.cir.19.5.705, PMID 13652363.
76. Ara I, Maqbool M, Zehravi M, IJAJCB. Gani, herbs boosting immunity in Covid-19: an

overview. 2020;3(3):289-94.
77. Sawan ZH, Soliman HM, Mostafa AEA. T.E.J.o.H.M. Kamel, A review on nitroglycerin: Present and future. R J. 2023;91(1):4972-4.
78. Zehravi M, Maqbool M, IJTIJoN. Ara, Dietetics, An overview about safety surveillance of adverse drug reactions and pharmacovigilance in India; 2021. p. 408-18.
79. Sorbets E, Steg PG, Young R, Danchin N, Greenlaw N, Ford I et al. β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. Eur Heart J. 2019;40(18):1399-407. doi: 10.1093/eurheartj/ehy811, PMID 30590529.
80. Maqbool M, Ara I. Gani, pharmacology, the story of polycystic ovarian syndrome: A challenging disorder with numerous consequences for females of reproductive age. I.J.I. Jo.C.R.i.P. 2022:19-31.
81. Bashir R, Maqbool M, Zehravi M, I.J.A.J.C.S.B. Ara, Utilization of herbal cosmetics: A brief overview. 2021;3:277-88.
82. Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty SJJocp. A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol. 2019;234(10):16812-23. doi: 10.1002/jcp.28350, PMID 30790284.
83. Zehravi M, Maqbool M, Ara IJAJoC, Section B. Curcumin–A promising phytocompound of immense potential. 2021;3:271.
84. Jia S, Liu Y, JJCADT, Yuan D. Discovery, Evidence in guidelines for treatment of coronary artery disease; 2020. p. 37-73.
85. Dar MA, Maqbool M, Ara IJJoEoM, D. Sciences, metformin and other sulfonylureas for glycemic control in Type 2 diabetic patients at a Tertiary Care Hospital in Jammu & Kashmir; 2023. p. 197-201.
86. Chen N, Chen L, Jiang S, Wang Z, Liu TJE, Medicine T. Predictive value of P selectin and endothelin-1 for vascular restenosis after interventional procedures for peripheral artery disease. Exp Ther Med. 2019;17(5):3907-12. doi: 10.3892/etm.2019.7407, PMID 30988775.
87. Dar MA, Maqbool M, Ara IJJoEoM, D. Sciences, patterns of drug use in geriatric patients at a Tertiary Care Teaching Hospital in Jammu And . Kashmir; 2023. p. 182-6.
88. Loffroy R, Falvo N, Galland C, Fréchier L, Ledan F, Midulla M et al. Intravascular ultrasound in the endovascular treatment of patients with peripheral arterial disease: current role and future perspectives. Front Cardiovasc Med. 2020;7:551861. doi: 10.3389/fcvm.2020.551861, PMID 33344512.
89. Dar MA, Maqbool M, Ara IJJoEoM, D. Sciences, prescription pattern of antibiotics in pulmonary ward of a tertiary. Jammu and Kashmir: Care Hospital; 2023. p. 171-5.
90. Arramraju S.K., Janapati R.K., Sanjeeva Kumar E., Mandala G.R. National interventional council data for the year 2018-India. Indian Heart J. 2020;72(5):351-5. doi: 10.1016/j.ihj.2020.07.018, PMID 33189193.
91. Willie MM, MJASRP. Maqbool, Access to public health services in South Africa’s rural Eastern Cape Province. 2023;1(2):35-54.
92. Darmoch F, Alraies MC, Al-Khadra Y, Moussa Pacha H, Pinto DS, EAJ.J.o.t.A.H.A. Osborn, Intravascular ultrasound imaging–guided versus coronary angiography–guided percutaneous coronary intervention: a systematic review and meta-analysis. 2020;9(5):e013678.
93. Mumtaz S, Behram F, Jadoon DK, Maqbool M, Shah SAA, Khawaja UFJN. Pattern of drug use in the dermatology department of a hospital for common skin conditions. 2022;20(16):2804.
94. Maqbool M, Nasir N. S.J.I.A.J.O.P.S. Mustafa, Polycystic in ovarian syndrome and its various treatment strategies. 2018;5(9):8470-8.
95. Völz S, Redfors B, Angerås O, Ioanes D, Odenstedt J, Koul S et al. Long-term mortality in patients with ischaemic heart failure revascularized with coronary artery bypass grafting or percutaneous coronary intervention: insights from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J. 2021;42(27):2657-64. doi: 10.1093/eurheartj/ehab273, PMID 34023903.
96. Li F, Shi G.W., Yu X.L., Song R.X., Xiao J.Q., Huang H.M. et al. Safety and efficacy of coronary angiography and percutaneous coronary intervention via distal transradial artery

access in the anatomical snuffbox: a single-centre prospective cohort study using a propensity score method. BMC Cardiovasc Disord. 2022;22(1):74. doi: 10.1186/s12872-022-02518-8, PMID 35236288.
97. Maqbool M, Naeem A, S.J.I.A.J.o.P.S. Aamer, diabetes mellitus and its various management strategies. Pract. 2018;5(8):8163-+.
98. Aoki J, Tanabe KJCI. Mechanisms of drug-eluting stent restenosis. Cardiovasc Interv Ther. 2021;36(1):23-9. doi: 10.1007/s12928-020-00734-7, PMID 33222019.
99. Maqbool M, Tariq S, S.J.I.A.J.o.P.S. Amjad, Prescribing practices in pediatrics and drug utilization studies promoting pediatric health. 2018;5(8):8070-6.
100. Kuramitsu S, Sonoda S, Ando K, Otake H, Natsuaki M, Anai R et al. therapeutics, Drug-eluting stent thrombosis: current and future perspectives. 2021;36:158-68.
101. Madhavan MV, Howard JP, Naqvi A, Ben-Yehuda O, Redfors B, Prasad M et al. Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J. 2021;42(27):2643-54. doi: 10.1093/eurheartj/ehab280, PMID 34002202.
102. Maqbool M, Javed S, AAJ.I.A.J.O.P.S. Bajwa, Assessment OF pain management IN postoperative cases using different scales and questionnaires. 2019;6(1):983-7.
103. Jinnouchi H, Torii S, Sakamoto A, Kolodgie FD, Virmani R, Finn A.V. Fully bioresorbable vascular scaffolds: lessons learned and future directions. Nat Rev Cardiol. 2019;16(5):286-304. doi: 10.1038/s41569-018-0124-7, PMID 30546115.
104. Baek S.W., Kim D.S., Song DH, Kim HB, Lee S, Kim JH et al. Reduced restenosis and enhanced re-endothelialization of functional biodegradable vascular scaffolds by everolimus and magnesium hydroxide. Biomater Res. 2022;26(1):86. doi: 10.1186/s40824-022-00334-x, PMID 36544178.
105. Maqbool M, Shabbir W. S.J.I.A.J.O.P.S. Aamir, Adverse events of blood transfusion and blood safety in clinical practice. 2018;5(8):8254-9.
106. Chaus A, Uretsky BFJCD. Bioresorbable vascular scaffolds: a dissolving dream?. Cardiovasc Drugs Ther. 2023;37(1):1-3. doi: 10.1007/s10557-022-07401-4, PMID 36374359.
107. Maqbool M, Ikram U. A.J.I.A.J.O.P.S. Anwar, Adverse drug reaction monitoring and occurrence in drugs used in pulmonary disorders. 2018;5(8):8060-5.
108. Sharma SK, Tomey MI, Teirstein PS, Kini AS, Reitman AB, Lee AC et al. North American expert review of rotational atherectomy. Circ Cardiovasc Interv. 2019;12(5):e007448. doi: 10.1161/CIRCINTERVENTIONS.118.007448, PMID 31084239.
109. Bouisset F, Barbato E, Reczuch K, Dobrzycki S, Meyer-Gessner M, Bressollette E et al., M.J.E.J.o.E.i.C.w.t.W.G.o.I.C.o.t.E.S.o.C. Clinical outcomes of PCI with rotational atherectomy: the European multicentre Euro4C registry. EuroIntervention. 2020;16(4):e305-12. doi: 10.4244/EIJ-D-19-01129, PMID 32250249.
110. Jin K, Khonsari S, Gallagher R, Gallagher P, Clark AM, Freedman B et al. Telehealth interventions for the secondary prevention of coronary heart disease: a systematic review and meta-analysis. Eur J Cardiovasc Nurs. 2019;18(4):260-71. doi: 10.1177/1474515119826510, PMID 30667278.
111. Rees K, Takeda A, Martin N, Ellis L, Wijesekara D, Vepa A et al. Stranges, Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease, (3); 2019.
112. Zyryanov SK, Fitilev SB, Vozzhaev AV, Shkrebniova II, Shindryaeva NN, Klyuev DA et al. Voronko, Medication adherence in patients with stable coronary artery disease in primary care. 2020;6(2):97-103.
113. Wadden TA, Tronieri JS, Butryn MLJAp. Lifestyle modification approaches for the treatment of obesity in adults. Am Psychol. 2020;75(2):235-51. doi: 10.1037/amp0000517, PMID 32052997.
114. Bhatti GK, Reddy AP, Reddy PH, JSJFian. Bhatti, Lifestyle modifications and nutritional interventions in aging-associated cognitive decline and Alzheimer’s disease. 2020;11:369.
115. Jepma P, Jorstad HT, Snaterse M, Ter Riet G, Kragten H, Lachman S et al. Lifestyle modification in older versus younger patients with coronary artery disease. Heart. 2020;106(14):1066-72. doi: 10.1136/heartjnl-2019-316056, PMID 32179587.

116. Piché M.E., Poirier P, Marette A, Mathieu P, Lévesque V, Bibeau K et al. Benefits of 1-year lifestyle modification program on exercise capacity and diastolic function among coronary artery disease men with and without type 2 diabetes. Metab Syndr Relat Disord. 2019;17(3):149-59. doi: 10.1089/met.2018.0092, PMID 30789304.
117. Ge C, Ma J, Xu Y, Shi Y.J., Zhao C.H., Gao L et al. Predictors of adherence to home-based cardiac rehabilitation program among coronary artery disease outpatients in China. J Geriatr Cardiol. 2019;16(10):749-55. doi: 10.11909/j.issn.1671-5411.2019.10.003, PMID 31700514.
118. Hong PC, Chen KJ, Chang YC, Cheng SM, HHJJoNS. Chiang, Effectiveness of theory-based health information technology interventions on coronary artery disease self-management behavior: a clinical randomized waitlist-controlled trial. 2021;53(4):418-27.
119. Arnold SV, Bhatt DL, Barsness GW, Beatty AL, Deedwania PC, Inzucchi SE et al. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association. Circulation. 2020;141(19):e779-806. doi: 10.1161/CIR.0000000000000766, PMID 32279539.
120. Turner BJ, Hollenbeak CS, Weiner M, Ten Have T, Tang S.S. Effect of unrelated comorbid conditions on hypertension management. Ann Intern Med. 2008;148(8):578-86. doi: 10.7326/0003-4819-148-8-200804150-00002, PMID 18413619.
121. Newland PK, Lorenz R, Budhathoki C, Jensen MPJCnr. The presence of symptoms with comorbid conditions in individuals with multiple sclerosis (MS). Clin Nurs Res. 2016;25(5):532-48. doi: 10.1177/1054773815592817, PMID 26122788.
122. Ferrari R, Abergel H, Ford I, Fox KM, Greenlaw N, Steg PG et al.J.I.j.o. cardiology, Gender- and age-related differences in clinical presentation and management of outpatients with stable coronary artery disease. 2013;167(6):2938-43.